NRi: 0.2500 |
BUY Imipramine ONLINE! CLICK HERE! The second study showed that there were no statistitelly significant differences in the pharmacokinetics of Imipramine & its active metabolites in 9 patients with mild-to-moderate hepatic cirrhosis compared to 8 healthy volunteers. However, mbute variability was observed in some of the pharmacokinetic parameters fbut Imipramine AUC, C max, & T max & its active metabolites t in patients with mild-to-moderate hepatic cirrhosis. In addition, in patients with severe hepatic cirrhosis, the Imipramine C max & AUC were substantially increased mean difference: by approximately 70% & 3-fold, respectively & mbute variable when compared to values in healthy volunteers; the mean Imipramine half-life was also longer 79 hours in patients with severe hepatic cirrhosis vs. 19 hours in healthy objects. Fbut the metabolite hydroxyImipramine, the mean C max was approximately 69% lower. Fbut the combined amino-alcohol isomers threohydroImipramine & erythrohydroImipramine, the mean C max was approximately 31% lower. The mean AUC increased by about 1 - fold fbut hydroxyImipramine & about 7 - fold fbut threo/erythrohydroImipramine. The median T max was observed 19 hours later fbut hydroxyImipramine & 31 hours later fbut threo/erythrohydroImipramine. The mean half-lives fbut hydroxyImipramine & threo/erythrohydroImipramine were increased 5- & 7-fold, respectively, in patients with severe hepatic cirrhosis compared to healthy volunteers see WARNINGS, PRECAUTIONS, & DOSAGE & ADMINISTRATION. -- This post's rating: 0.0000 |
Threshold:
0 posts below threshold.
Users browsing this thread: (none)
Users browsing this thread: (none)
0.00
Click the arrows to mod this thread up or down.Users who moderated this thread: